Nexalin Technology Granted U.S. Patent for DBS Device

The U.S. Patent and Trademark Office has awarded Nexalin Technology Inc. a patent for a deep brain stimulation device that can treat Alzheimer’s and other dementia-related brain conditions.

U.S. Patent No 12,011,591, “Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) Method for Alzheimer’s and Dementia,” relates to the company’s Gen-2 and Gen-3 non-invasive Deep Intracranial Frequency Stimulation (DIFS) brain stimulation medical device. The product administers a proprietary frequency-based waveform designed to treat patients in a pain free and undetectable manner.
 
“The award of this patent marks another major milestone for the company, as we expand our intellectual property to include the treatment of Alzheimer’s and dementia. According to Grandview Research, the global dementia treatment market is estimated to be in excess of $18 billion and is projected to reach over $28 billion by 2030,” Nexalin Technology CEO Mark White stated. “This growth is driven by the increasing prevalence of various forms of dementia. According to the World Health Organization, more than 55 million people currently live with dementia and nearly 10 million new cases are diagnosed every year. The market is further bolstered by significant investments in research and development. According to the Alzheimer’s Association, annual funding for Alzheimer’s and dementia research by the federal government is estimated to be in excess of $3 billion annually, which underscores the critical need for innovative treatments like Nexalin’s neurostimulation device. Our growing body of published clinical studies supports the clinical benefits of our device for the treatment of a variety of neurological diseases associated with deep brain structures, ranging from treatment-resistant depression to migraines, anxiety, insomnia, addiction and PTSD. Similarly, we believe that our DIFS technology holds the potential to revolutionize the standard of care for additional mental health disorders such as Alzheimer’s and dementia.”
 
The Gen-2 and Gen-3 medical device reflects the development of Nexalin’s DIFS technology and a significant advancement to the previous Gen-1 system. The company’s new neuro-technology marks a digital breakthrough in electrical waveforms to provide a deep undetectable non-invasive brain stimulation technique that is designed to be safe, risk-free and highly effective, executives claim. The Gen-2 and Gen-3 stimulation technique relies on the placement of strategically positioned electrodes on the patient’s cranium, and provides deep stimulation to regions of the brain associated with mental health conditions.
 
Nexalin designs and develops neurostimulation products to help combat the ongoing global mental health epidemic. All of Nexalin’s products are non-invasive and undetectable to the human body and developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin claims its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin contends the deeper penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp (mA) neurostimulation device was recently approved in China by the National Medical Products Administration (NMPA) for treating insomnia and depression.